Tag: Cancer: Lymphoma
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
Age-adjusted rate of developing BIA-ALCL 16 times higher for women with mutations versus without
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
Increased risks seen based on twin cohort and case-cotwin studies
Position Statement Developed for Managing Blood Cancers in Pregnancy
Multidisciplinary collaborative approach to care is required for patients with hematological malignancies in pregnancy
ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone
Late-Stage Lymphoma Less Likely for Young With Continuous Medicaid Coverage
Those with newly gained Medicaid, with other Medicaid enrollment patterns more likely to present with stage IV lymphoma
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard...
Most common SPM subtypes were hematologic malignancies followed by solid tumors, nonmelanoma skin cancers
Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
Nonrelapse mortality was driven by ICANS in early follow-up period, followed by infection through three months
